Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Levy

Clinical Cardiac Electrophysiology San Jose, CA Medical Doctor

NPI 1649334079 CMS profile 29218

2581 Samaritan Drive, Suite 202, San Jose, CA 95124

Open in the dashboard

General payments

$29,909

104 records reported · program years 2019–2025

Research payments

$123

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,421 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Matthew Levy of San Jose, CA is reported in the CMS Open Payments database as having received $29,909 across 104 general payments and $123 in research payments paid to them. Separately, studies naming them as principal investigator received $13,421 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,599 25
2024 General $13,811 25
2023 General $316 4
2022 General $477 5
2021 General $779 14
2020 General $303 7
2019 General $4,625 24
2019 Research $123 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Levy
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Matthew Levy were reported at $9,599. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Matthew Levy Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,625 $2,361 $585–$8,260 $163
2020 $303 $993 $247–$4,351 $114
2021 $779 $1,185 $326–$4,739 $132
2022 $477 $2,073 $554–$6,789 $149
2023 $316 $2,568 $759–$8,159 $160
2024 $13,811 $2,557 $703–$7,403 $164
2025 $9,599 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $23,549 47 payments
  2. Janssen Pharmaceuticals, Inc $3,846 5 payments
  3. Boston Scientific Corporation $553 20 payments
  4. Medtronic Vascular, Inc. $476 4 payments
  5. Medtronic, Inc. $367 3 payments
  6. Biosense Webster, Inc. $330 7 payments
  7. Atricure, Inc. $276 4 payments
  8. Abbott Laboratories $109 5 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $108 2 payments
  10. Acutus Medical, Inc. $104 1 payment
  11. Other $191 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,840 13 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $8,350 4 payments
  3. Food and Beverage $5,032 84 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,600 2 payments
  5. Education $87 1 payment
Products named General payments · program years 2019–2025
  1. Selectra $11,262 12 payments
  2. Solia $11,133 12 payments
  3. XARELTO $3,852 6 payments
  4. RHYTHMIA $300 12 payments
  5. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $276 4 payments
  6. Carto 3 $268 4 payments
  7. Attain $192 1 payment
  8. AMVIA EDGE $179 1 payment
  9. SelectSecure Leads $173 1 payment
  10. SelectSecure Leads $160 1 payment
  11. Other $913 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $123 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,050

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$711,586

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

43.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 355 $475,047
Xarelto Rivaroxaban Brand 156 $194,084
Flecainide Acetate Generic 330 $16,396
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 137 $5,131
Metoprolol Succinate Generic 293 $5,042
Sotalol Af Sotalol Hcl Brand 94 $3,570
Propafenone Hcl Er Propafenone Hcl Brand 14 $2,320
Amiodarone Hcl Generic 100 $1,978
Sotalol Sotalol Hcl Brand 94 $1,804
Potassium Chloride Generic 33 $1,129

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$462,217

Medicare's payments for the services billed

Medicare patients

1,033

Average age 79

Services billed

6,125

479 women, 554 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 68%
Arthritis 41%
Ischemic heart disease 39%
Heart failure 32%
Diabetes 29%
Chronic kidney disease 29%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $26
$26 355 —
XARELTO
  • Janssen Pharmaceuticals, Inc $22
$22 156 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record